# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2023 Earnings Results

**Report date:** 2023-08-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2023

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 5.37%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $10.24 | N/A | +20.74% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed satisfaction with the earnings results, highlighting their commitment to innovation. They emphasized ongoing efforts to enhance their product offerings.

**Key quotes:**

> The company is pleased with the strong performance this quarter.

> We continue to focus on innovation and expanding our product pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates robust profitability, which likely contributed to the positive stock reaction of 5.37%. Investors may view this as a sign of the company's resilience and potential for future growth, despite the lack of revenue data and guidance. The focus on innovation suggests that Regeneron is positioning itself well in the competitive pharmaceutical landscape.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2023_